Kayexalate lowers high potassium levels in your blood by swapping sodium for potassium inside your gut. It’s a powdered resin that you swallow as a liquid suspension or, less commonly, receive as an enema. The potassium it captures gets carried out of your body in your stool rather than staying in your bloodstream, where excess levels can be dangerous to your heart.
How Kayexalate Removes Potassium
Kayexalate is a cation-exchange resin, which is a fancy way of saying it trades one mineral for another. The resin is loaded with sodium. As it travels through your intestines, potassium in your gut attaches to the resin, and sodium is released in its place. The resin, now carrying potassium, passes out of your body when you have a bowel movement.
In a lab setting, each gram of Kayexalate can grab about 3.1 milliequivalents (mEq) of potassium. Inside the body, that efficiency drops to roughly 1 mEq per gram, meaning only about a third of the resin’s exchange capacity actually works in practice. That matters because each gram also contains 4.1 mEq of sodium, and about a third of that sodium gets absorbed into your body during the exchange. So for every unit of potassium removed, you’re taking in a meaningful amount of sodium.
Why It’s Prescribed
Kayexalate is used to treat hyperkalemia, the medical term for potassium levels that are too high. Your body needs potassium for muscle contractions, nerve signals, and a steady heartbeat, but when levels climb beyond the normal range, the consequences can be serious. Dangerously high potassium can cause muscle weakness, numbness, and irregular heart rhythms that, in severe cases, become life-threatening.
People with kidney disease are especially prone to hyperkalemia because their kidneys can’t flush excess potassium efficiently. Certain medications, including some blood pressure drugs and anti-inflammatory painkillers, can also push potassium levels up. In these situations, Kayexalate serves as a way to pull potassium out through the digestive tract instead of relying on the kidneys.
How It’s Taken
The typical adult dose ranges from 15 to 60 grams per day, usually split into one to four doses. Each 15-gram dose is roughly four level teaspoons of the powder, mixed into a small amount of water or flavored syrup to make it easier to drink. The volume of liquid depends on the dose but generally falls between 20 and 100 milliliters.
When someone can’t take Kayexalate by mouth, it can be given as a retention enema. The rectal route uses a larger dose, typically 30 to 50 grams suspended in about 100 milliliters of a warm liquid, administered every six hours. This method is considered less effective than taking it orally because the resin spends less time in contact with the full length of the intestines.
How Quickly It Works
Kayexalate is not a fast-acting treatment. Its onset is highly variable, which makes it a poor choice when potassium needs to come down within minutes. In emergency settings, doctors typically use faster interventions first, like insulin with glucose or inhaled medications that temporarily shift potassium from the bloodstream into cells. Kayexalate is better suited for situations where potassium needs to be lowered gradually or kept in check over hours to days.
The Sodium Trade-Off
Because Kayexalate works by exchanging sodium for potassium, it introduces extra sodium into your system. For people who are sensitive to sodium, such as those with heart failure, severe high blood pressure, or significant fluid retention, this added sodium load can worsen swelling and raise blood pressure. Your care team will monitor your electrolytes during treatment, checking not just potassium but also sodium, calcium, and magnesium levels, since the resin’s binding isn’t perfectly selective and can pull other minerals out of your gut as well.
Side Effects and Safety Concerns
The most common side effects are digestive: nausea, vomiting, constipation, and stomach discomfort. These are generally manageable, but Kayexalate carries a more serious risk that sets it apart from some alternatives.
The FDA has flagged cases of colonic necrosis, a condition where part of the colon’s tissue dies, along with intestinal bleeding, reduced blood flow to the colon, and bowel perforation. These events are rare but potentially fatal. Risk factors include a history of intestinal disease or surgery, dehydration, and kidney failure. Premature and low-birth-weight infants face particular danger.
An older practice of mixing Kayexalate with sorbitol, a sweetener that also acts as a laxative, has been implicated in many of these bowel injury cases. The FDA now explicitly recommends against combining the two. Magnesium-containing laxatives should also be avoided during treatment.
How It Compares to Newer Options
Kayexalate has been around for decades, and two newer potassium-lowering resins are now available. One, sodium zirconium cyclosilicate (sold as Lokelma), was approved in 2018 and has been shown to lower potassium within one hour of a single dose in clinical trials. The other, patiromer (sold as Veltassa), uses calcium instead of sodium for the exchange, which avoids the sodium-loading problem entirely.
In terms of raw potassium reduction, Kayexalate and sodium zirconium cyclosilicate performed similarly in emergency department comparisons, both lowering potassium by an average of 1.1 mEq/L from baseline. The difference lies more in the side-effect profile. Kayexalate’s non-selective binding can disturb calcium and magnesium levels on top of adding sodium. Sodium zirconium cyclosilicate is highly selective for potassium, contains considerably less sodium, and carries a milder side-effect profile, mostly limited to digestive symptoms and mild swelling.
Despite these newer alternatives, Kayexalate remains widely used. Cost, insurance coverage, and hospital formulary decisions all play a role in which agent a patient receives. If you’ve been prescribed Kayexalate and have concerns about sodium intake or bowel health, those are worth raising with whoever is managing your treatment.